NO20073414L - Monoklonale antistoffer mot angiopotetin-lignede protein 4 (ANGPTL4) - Google Patents

Monoklonale antistoffer mot angiopotetin-lignede protein 4 (ANGPTL4)

Info

Publication number
NO20073414L
NO20073414L NO20073414A NO20073414A NO20073414L NO 20073414 L NO20073414 L NO 20073414L NO 20073414 A NO20073414 A NO 20073414A NO 20073414 A NO20073414 A NO 20073414A NO 20073414 L NO20073414 L NO 20073414L
Authority
NO
Norway
Prior art keywords
monoclonal antibodies
angptl4
angiopotetin
protein
neutralizing
Prior art date
Application number
NO20073414A
Other languages
English (en)
Inventor
E-Chiang Lee
Gregory M Landes
Kuy Chung
Ling Chen
Urvi Desai
David Reed Powell
Seokjoo Hong
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of NO20073414L publication Critical patent/NO20073414L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SAMMENDRAG Monoklonale antistoffer som spesifikt bindes til ANGPTL4, er tilveiebrakt. Monoklonale antistoffer som nøytraliserer minst én aktivitet av ANGPTL4, er tilveiebrakt. Fremgangsmåter for behandling av en forstyrrelse i lipidmetabolismen ved anvendelse av nøytraliserende monoklonale antistoffer er tilveiebrakt.
NO20073414A 2005-01-07 2007-07-03 Monoklonale antistoffer mot angiopotetin-lignede protein 4 (ANGPTL4) NO20073414L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64202205P 2005-01-07 2005-01-07
PCT/US2006/000184 WO2006074228A1 (en) 2005-01-07 2006-01-06 Monoclonal antibodies against angiopoietin-like protein 4 (angptl4 )

Publications (1)

Publication Number Publication Date
NO20073414L true NO20073414L (no) 2007-10-02

Family

ID=36177590

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073414A NO20073414L (no) 2005-01-07 2007-07-03 Monoklonale antistoffer mot angiopotetin-lignede protein 4 (ANGPTL4)

Country Status (14)

Country Link
US (3) US7655762B2 (no)
EP (1) EP1846452B1 (no)
JP (1) JP5366406B2 (no)
KR (1) KR101387781B1 (no)
CN (1) CN101128485B (no)
AU (1) AU2006204001B2 (no)
BR (1) BRPI0606432A2 (no)
CA (1) CA2594233C (no)
EA (1) EA016185B1 (no)
IL (1) IL184235A (no)
MX (1) MX2007008256A (no)
NO (1) NO20073414L (no)
WO (1) WO2006074228A1 (no)
ZA (1) ZA200705980B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
CN101080419B (zh) 2004-07-20 2014-07-02 健泰科生物技术公司 利用血管生成素样4蛋白的组合物和方法
BRPI0513534A (pt) * 2004-07-20 2008-05-06 Genentech Inc inibidores de proteìna 4 semelhante à angiopoietina, combinações, e seu uso
PL2121751T3 (pl) 2006-12-08 2017-07-31 Lexicon Pharmaceuticals, Inc. Przeciwciała monoklonalne przeciwko ANGPTL3
SG10201406420XA (en) * 2009-10-14 2014-11-27 Univ Nanyang Tech Antiproliferative agent
JO3274B1 (ar) * 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
US9520226B2 (en) * 2011-04-08 2016-12-13 Access Business Group International Llc Counter wound inductive power supply
CN102242198A (zh) * 2011-05-25 2011-11-16 信阳师范学院 通过angptl4基因多态性进行牛育种方法
EP2742361A4 (en) * 2011-08-08 2015-03-04 Univ Nanyang Tech ANGIOPOIETIN-LIKE 4 AND ITS USE FOR MODULATING THE POROSITY OF CELLS
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
KR20150008383A (ko) * 2012-04-16 2015-01-22 리제너론 파아마슈티컬스, 인크. 세린 프로테아제 억제제의 투여에 의한 인플루엔자 바이러스 감염의 치료 또는 예방 방법
GB201301313D0 (en) * 2013-01-25 2013-03-06 Univ Singapore Respiratory Tract Infections
TW201613977A (en) * 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
WO2016020880A2 (en) * 2014-08-07 2016-02-11 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
SG11201803520PA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
CA3117750A1 (en) * 2018-11-13 2020-05-22 Lipigon Pharmaceuticals Ab Angptl4 oligonucleotides influencing the regulation of the fatty acid metabolism
WO2021087114A1 (en) * 2019-10-29 2021-05-06 University Of Florida Research Foundation, Incorporated Anti-angiopoietin-like 4 (angptl4) antibodies and methods of use
CN115708872A (zh) * 2022-11-03 2023-02-24 中国科学院深圳先进技术研究院 抗血管生成素样蛋白4抗体在制备抑制炎症因子表达的药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
AU4643699A (en) 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
AU2001249929A1 (en) 2000-04-07 2001-10-23 Dana-Farber Cancer Institute Inc. Fdrg proteins and nucleic acid molecules and uses therefor
NL1017421C2 (nl) 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
CN1141318C (zh) * 2001-02-28 2004-03-10 中国医学科学院血液学研究所 人促血液血管细胞生成素及其制造方法
WO2003010205A1 (en) * 2001-07-26 2003-02-06 Duke University Medical Center Genes induced by hypoxia
CN101080419B (zh) * 2004-07-20 2014-07-02 健泰科生物技术公司 利用血管生成素样4蛋白的组合物和方法
BRPI0513534A (pt) * 2004-07-20 2008-05-06 Genentech Inc inibidores de proteìna 4 semelhante à angiopoietina, combinações, e seu uso

Also Published As

Publication number Publication date
US20110008359A1 (en) 2011-01-13
CN101128485B (zh) 2012-09-26
IL184235A (en) 2012-10-31
US20120171217A1 (en) 2012-07-05
US7655762B2 (en) 2010-02-02
CA2594233C (en) 2015-02-24
MX2007008256A (es) 2007-12-06
US8092796B2 (en) 2012-01-10
AU2006204001A1 (en) 2006-07-13
CN101128485A (zh) 2008-02-20
KR20070107696A (ko) 2007-11-07
JP2008526857A (ja) 2008-07-24
KR101387781B1 (ko) 2014-04-21
US8591891B2 (en) 2013-11-26
EA016185B1 (ru) 2012-03-30
IL184235A0 (en) 2007-10-31
EP1846452A1 (en) 2007-10-24
JP5366406B2 (ja) 2013-12-11
EP1846452B1 (en) 2014-08-06
ZA200705980B (en) 2009-01-28
CA2594233A1 (en) 2006-07-13
US20060222645A1 (en) 2006-10-05
WO2006074228A1 (en) 2006-07-13
EA200701452A1 (ru) 2008-02-28
BRPI0606432A2 (pt) 2009-06-30
AU2006204001B2 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
NO20073414L (no) Monoklonale antistoffer mot angiopotetin-lignede protein 4 (ANGPTL4)
NO20092215L (no) Monoklonale antistoffer mot ANGPTL3
NO2017032I1 (no) bezlotoksumab
LTPA2017040I1 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
PH12015501848A1 (en) Binding agents
DK1629011T3 (da) Humane anti-humane-DC3-bindingsmolekyler
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
BR0315161A (pt) Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição
MY174493A (en) Binding agents
AR083747A1 (es) Anticuerpos anti-il-23
CR9471A (es) Anticuerpos de p-caderina
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
WO2007116360A3 (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
WO2008134724A3 (en) Methods for administering anti-il-5 antibodies
WO2009008916A3 (en) Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
NO20092743L (no) Antistoffer mot CD200R
DK1861711T3 (da) Anvendelse af MGC4504

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application